Artesunate Regimen for Severe Malaria
For severe or complicated malaria in adults and children, administer intravenous artesunate at 2.4 mg/kg at 0,12, and 24 hours, then continue with 2.4 mg/kg daily until the patient can tolerate oral therapy and parasitemia is <1%. 1
Initial Intravenous Phase
The standard IV artesunate regimen consists of:
- 2.4 mg/kg IV bolus at time 0,12 hours, and 24 hours
- Then 2.4 mg/kg IV daily thereafter 1
This represents the first-line treatment for all species of severe/complicated malaria and is superior to quinine in reducing mortality. In the landmark SEAQUAMAT trial, artesunate reduced mortality by 34.7% compared to quinine (15% vs 22% mortality; p=0.0002) 2. The drug has rapid onset of action and is safer than quinine, avoiding the hypoglycemia risk associated with quinine (relative risk 3.2) 2.
Transition Criteria to Oral Therapy
Switch to oral artemisinin-based combination therapy (ACT) when BOTH conditions are met:
- Patient can tolerate oral medications
- Parasitemia drops below 1% 1
If parasitemia remains >1% or oral intake is not feasible, continue IV artesunate 2.4 mg/kg daily for up to 7 days total. 1
Oral Continuation Regimens (Preferred Options)
Once transition criteria are met, complete treatment with a full course of:
- Dihydroartemisinin-piperaquine (DHA-PPQ) - preferred due to longer half-life 1
- Artemether-lumefantrine (AL) - alternative ACT
- Atovaquone-proguanil or mefloquine if ACTs unavailable 1
The 2024 Clinical Microbiology and Infection guidelines emphasize that artemisinin-based oral regimens are preferred for continuation therapy 1.
Simplified Regimens (Evidence-Based Alternatives)
Research supports simplified dosing in resource-limited settings:
- Three-dose IM regimen: 4 mg/kg at 0,24, and 48 hours (total 12 mg/kg) demonstrated non-inferiority to the five-dose regimen in African children 3
- Three-dose IV regimen: Studies show comparable efficacy, though the 2024 guidelines maintain the standard regimen as first-line 4
Critical Monitoring Requirements
Monitor hemoglobin at day 14 post-treatment - approximately 10-15% of patients develop post-artesunate delayed hemolysis (PADH), requiring surveillance 5, 1
Common pitfalls to avoid:
- Do not wait for injectable artesunate availability if unavailable - start IV quinine immediately as second-line (20 mg salt/kg loading dose over 4 hours, then 10 mg/kg every 8 hours) 1
- Do not discharge patients with severe malaria before completing at least 48 hours of IV therapy 1
- Do not use oral therapy as initial treatment for severe malaria regardless of ability to swallow 1
Special Populations
Pregnancy (any trimester): Use artesunate over quinine for severe malaria - the mortality benefit outweighs theoretical first-trimester concerns 5, 1
Children: Same weight-based dosing (2.4 mg/kg) applies; consider empirical broad-spectrum antibiotics until bacterial co-infection excluded 5
Pre-Referral Treatment
In remote settings where IV access is impossible, rectal artesunate 10 mg/kg provides effective pre-referral treatment with comparable dihydroartemisinin exposure to IV administration, though bioavailability is variable (mean 21%) 6, 7. This should be followed by definitive parenteral therapy upon reaching a facility.
The evidence strongly supports artesunate as superior to quinine for severe malaria, with the 2024 guidelines from Clinical Microbiology and Infection providing the most current treatment algorithms 1. The regimen is straightforward, well-tolerated, and has transformed severe malaria outcomes with a 35% mortality reduction compared to historical quinine-based treatment 2.